Check for updates

OPEN ACCESS

EDITED BY Paulo Gavaia, University of Algarve, Portugal

REVIEWED BY Berenice Rivera-Paredez, National Autonomous University of Mexico, Mexico Márcio Simão, University of Algarve, Portugal

*CORRESPONDENCE Xuetao Wang, ⊠ 18317521548@163.com

[†]These authors have contributed equally to this work

RECEIVED 29 November 2023 ACCEPTED 24 May 2024 PUBLISHED 07 June 2024

CITATION

Yuan K, Xie X, Huang W, Li D, Zhao Y, Yang H and Wang X (2024), Elucidating causal relationships of diet-derived circulating antioxidants and the risk of osteoporosis: A Mendelian randomization study. *Front. Genet.* 15:1346367. doi: 10.3389/fgene.2024.1346367

COPYRIGHT

© 2024 Yuan, Xie, Huang, Li, Zhao, Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Elucidating causal relationships of diet-derived circulating antioxidants and the risk of osteoporosis: A Mendelian randomization study

Kexin Yuan^{1†}, Xingwen Xie^{2†}, Weiwei Huang¹, Dingpeng Li³, Yongli Zhao², Haodong Yang¹ and Xuetao Wang¹*

¹Gansu University of Chinese Medicine, Lanzhou, China, ²Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, China, ³The Second People's Hospital of Gansu Province, Lanzhou, China

Background: Osteoporosis (OP) is typically diagnosed by evaluating bone mineral density (BMD), and it frequently results in fractures. Here, we investigated the causal relationships between diet-derived circulating antioxidants and the risk of OP using Mendelian randomization (MR).

Methods: Published studies were used to identify instrumental variables related to absolute levels of circulating antioxidants like lycopene, retinol, ascorbate, and β -carotene, as well as antioxidant metabolites such as ascorbate, retinol, α -tocopherol, and γ -tocopherol. Outcome variables included BMD (in femoral neck, lumbar spine, forearm, heel, total body, total body (age over 60), total body (age 45–60), total body (age 30–45), total body (age 15–30), and total body (age 0–15)), fractures (in arm, spine, leg, heel, and osteoporotic fractures), and OP. Inverse variance weighted or Wald ratio was chosen as the main method for MR analysis based on the number of single nucleotide polymorphisms (SNPs). Furthermore, we performed sensitivity analyses to confirm the reliability of the findings.

Results: We found a causal relationship between absolute retinol levels and heel BMD (p = 7.6E-05). The results of fixed effects IVW showed a protective effect of absolute retinol levels against heel BMD, with per 0.1 ln-transformed retinol being associated with a 28% increase in heel BMD (OR: 1.28, 95% CI: 1.13–1.44). In addition, a sex-specific effect of the absolute circulating retinol levels on the heel BMD has been observed in men. No other significant causal relationship was found.

Conclusion: There is a positive causal relationship between absolute retinol levels and heel BMD. The implications of our results should be taken into account in future studies and in the creation of public health policies and OP prevention tactics.

KEYWORDS

diet-derived antioxidants, oxidative stress, osteoporosis, bone mineral density, fractures, Mendelian randomization

1 Introduction

Osteoporosis (OP), recognized as the most prevalent systemic bone disorder, is primarily identified by reduced bone mineral density (BMD) and an increased incidence of brittle fractures resulting from the weakening of bone microarchitecture (Song et al., 2022). This deterioration can escalate the risk of severe disability or mortality, especially among older adults (Borgström et al., 2020). The universally accepted diagnostic approach for OP involves measuring BMD utilizing dual-energy x-ray absorptiometry, a technique that assesses BMD at specific skeletal sites including the femoral neck, lumbar spine, and forearm, which are particularly susceptible to changes in BMD and overall bone health (Kanis, 1997; Kanis, 2002). Additionally, in more recent times, the heel site has emerged as an additional location for estimating OP, further expanding the scope of diagnostic evaluation (Bai et al., 2020). Moreover, measuring total body BMD (TB-BMD) is also considered an equally valid and unbiased approach for evaluating overall BMD in the context of OP diagnosis. Fractures, another significant manifestation of OP, occur most commonly in the leg, arm, heel, and spine, further highlighting the widespread impact of the disease on skeletal integrity (Liu et al., 2019; Black et al., 2020; Leder et al., 2020). According to the most recent findings published by the International Osteoporosis Foundation, it is estimated that globally, one in three women and one in five men who are above the age of 50 are likely to suffer from OP (Cui et al., 2018; Liu et al., 2019; Black et al., 2020; Leder et al., 2020). This statistic not only reflects the extensive prevalence of this disease but also emphasizes the profound effect OP has on the quality of life of patients, as well as the substantial challenge it poses to public health infrastructures and national economies.

Oxidative stress occurs when there is an imbalance between oxidative and antioxidative processes in the body, a condition that significantly contributes to aging and various diseases (Mladenov et al., 2023). This imbalance is largely regulated by reactive oxygen species (ROS) and various antioxidant enzymes. Increasingly, studies are showing that bone health is largely influenced by the regulation of redox balance, with the control of ROS production in bone cells emerging as a critical strategy for preventing bone deterioration (Kaur et al., 2021). The activation of osteoclasts by receptor activator of NF-kB ligand (RANKL) through binding to RANK receptors on the surface of osteoclasts induces the formation of multinucleated giant cells, subsequently facilitating bone resorption and remodeling (Liang et al., 2023). The interaction between RANKL and ROS plays a key role in osteoclast activation and bone remodeling, forming a positive feedback loop to influence bone metabolic homeostasis (Tanaka et al., 2023; Xu et al., 2023). While the superoxide produced by osteoclasts plays a direct role in bone degradation, osteoblasts synthesize antioxidants like glutathione peroxidase (GPX) to combat ROS (Yuan et al., 2022). As a result, in scenarios where there is an imbalance between ROS production and antioxidant defense, it can adversely impact bone metabolism, potentially leading to OP (López-Armada et al., 2022). In addition, recent studies have shown that oxidative stress is involved in the pathogenesis of OP by uncoupling osteoclast and osteoblast functions (Baek et al., 2010; Manolagas, 2018). Using pathways of bone metabolism, such uncoupling can be achieved by promoting osteoclastogenesis, inducing apoptosis of osteoblasts and osteocytes, and inactivating osteoblasts (Kimball et al., 2021). Dietary antioxidants are commonly recognized as the most readily available source of antioxidant defense. Therefore, antioxidants, especially those from dietary sources, have an important role to play in the prevention of OP. There has been some research examining the relationship between certain dietary antioxidants and bone health in humans in the past (Sugiura et al., 2011; Talaulikar et al., 2012). Consuming more fruits, vegetables, and cereals reduces fracture risk, according to Warensjö et al. in a study of 56,736 women (Warensjö Lemming et al., 2017). Similar conclusions have been reached in other studies: natural antioxidant-rich plant foods can improve BMD (Platt et al., 2011; Wallace, 2017). Although diet-based supplements are easily accessible and affordable, it remains critical to identify specific circulating antioxidants that are causally associated with reduced risk of OP.

Randomized controlled trials (RCTs) are widely regarded as the most reliable method for determining causal relationships (Tew et al., 2023). However, RCTs may not always be feasible due to their potential high cost and ethical concerns. Additionally, the dosage and duration of antioxidant supplementations may limit the conclusions drawn from RCTs. As we know, it seems unrealistic to expect a few years of antioxidant treatment to reverse the effects of decades of oxidative stress. To address these limitations, an alternative statistical approach to explore causality in exposureoutcome relationships involves the utilization of instrumental variables. Specifically, Mendelian randomization (MR) is a powerful analytical method that uses genetic variation to study the causal impacts of risk factors on traits (Lawlor et al., 2008; Evans and Davey Smith, 2015; Burgess et al., 2019). Previous research using MR analysis has suggested possible causal links between levels of circulating antioxidants and a range of health conditions (Ni et al., 2023; Tang et al., 2023; Zhu et al., 2023; Chen et al., 2024; Zou et al., 2024). The primary objective of this study was to investigate the causal connection between diet-derived circulating antioxidants and the risk of OP.

2 Materials and methods

2.1 Study design

The present study explored the causal relationship between circulating antioxidants and the risk of BMD, fractures, and OP using MR analysis based on Genome-wide association study (GWAS) summary data. For this purpose, we obtained two independent data sets regarding antioxidants: absolute circulating antioxidants and circulating antioxidant metabolites. Here, "absolute circulating antioxidants" refer to the genuine absolute blood levels, while "circulating antioxidant metabolites" denote relative concentrations. To ensure robustness in our MR analysis, it was imperative that all instrumental variables related to circulating antioxidants conform to three primary assumptions (Figure 1A). The overall design of this study was presented in Figure 1B. The data used in this study were obtained from publicly available databases, so ethical approval was not required.



MR study design.

2.2 Genetic instrumental variables selection

For absolute circulating ascorbate, retinol, and β -carotene, we set the following criteria to screen instrumental variables: $p < 5 \times 10^{-8}$, $r^2 < 0.001$, and kb = 10,000. However, no SNP for lycopene was filtered based on the criterion of $p < 5 \times 10^{-8}$. Therefore, $p < 5 \times 10^{-6}$, $r^2 < 0.001$, and kb = 10,000 were used as screening criteria. Overall, we screened 11 SNPs significantly associated with ascorbate from a recently published GWAS summary data involving

52,018 individuals (Zheng et al., 2021). After further analysis, the rs7740812 was excluded from the list of ascorbate-related SNPs due to linkage disequilibrium (LD) clumping. In a meta-analysis of GWAS involving 5,006 participants, we identified two independent SNPs associated with retinol (Mondul et al., 2011). In a GWAS from the Nurses' Health Study, which included 2,344 participants, we identified two significantly associated SNPs for β -carotene (Hendrickson et al., 2012). One of the two identified SNPs, rs12934922, was later removed after LD clumping. In a

TABLE 1 Details for selected GWAS of confounders.

Confounders	Sample size	PMID
body mass index	681,275	30,124,842
Alcoholic drinks per week	335,394	30,643,251
Moderate to vigorous physical activity levels	377,234	29,899,525

GWAS involving 441 older Amish adults, we identified five independent SNPs associated with lycopene (D Adamo et al., 2016). Information on the GWAS cohort is provided in Supplementary Table S1.

For antioxidant metabolites, due to the lack of sufficient instrumental variables to perform MR analyses using strict screening criteria, we used looser thresholds ($p < 1 \times 10^{-5}$, $r^2 < 0.001$, and kb = 10,000). The threshold has also recently been used to explore the causal relationship between antioxidants and osteoarthritis (Tang et al., 2023), inflammatory bowel disease (Zou et al., 2024), and digestive system tumors (Zhang et al., 2022). In brief, a GWAS with 7,824 participants identified independent SNPs linked to blood metabolites of α -tocopherol (n = 11), γ -tocopherol (n = 13), and ascorbate (n = 14) (Shin et al., 2014). For retinol, we extracted 26 SNPs as instrumental variables from a GWAS involving 1960 participants (Long et al., 2017).

According to previous reports, body mass index (BMI), alcohol consumption, and physical activity levels may be risk factors for OP (Kanis et al., 2019; Arceo-Mendoza and Camacho, 2021). To avoid the influence of confounders on the results, we obtained the largest GWAS to date on BMI, alcoholic drinks per week, and moderate-to-vigorous physical activity (Table 1). If antioxidant-related SNPs were also significant in the confounders, these SNPs were eliminated. To assess the strength of the instrumental variables, the *F*-statistic was also calculated (Palmer et al., 2012).

2.3 Outcome data sources

It is well known that BMD loss in the forearm (FA-BMD), femoral neck (FN-BMD), lumbar spine (LS-BMD), and heel (eBMD) significantly increases the risk of OP and fractures more than in other parts of the body. Therefore, this study focuses on analyzing the causal relationship between circulating antioxidants and BMD in these four critical body parts. The GWAS summary data for FA-BMD, FN-BMD, and LS-BMD were obtained from the Genetic Factors for Osteoporosis Consortium (GEFOS) (Zheng et al., 2015), with participant numbers being 8,143, 32,735, and 28,498 respectively. Summary data for eBMD were derived from the United Kingdom Biobank (Wu et al., 2019), encompassing a total of 265,627 participants. The methodologies for measuring BMD have been elaborated in the original publication. Age is widely recognized as a risk factor for OP (Hadji et al., 2019). Hence, a comprehensive GWAS meta-analysis was employed to acquire detailed statistics on total body BMD (TB-BMD) across five age groups (under 15, 15-30, 30-45, 45-60, and above 60 years) (Medina-Gomez et al., 2018), involving 66,628 participants in total. OP leading to fractures is one of the most prevalent clinical symptoms (Wright et al., 2017). Therefore, GWAS summary data for fractures of the arm (AF; number of cases = 4,714, number of controls = 455,626), spine (SF; number of cases = 1,036, number of controls = 459,304), leg (LF; number of cases = 2,988, number of controls = 457,352), and heel (HF; sample size = 306,379) were obtained from the MRC-IEU database (Hemani et al., 2018). Furthermore, GWAS summary data for osteoporosis-related fractures (OPF; number of cases = 785, number of controls = 172,834) and OP (number of cases = 3,203, number of controls = 209,575) were downloaded from the FinnGen study (Kurki et al., 2023). The detailed data information for outcome is available in Table 2.

2.4 Statistical analysis

Figure 1B displays the main approach used for MR analysis. First, the major effector allele of the SNPs was used to harmonize the exposure and outcome information. We removed SNPs that were inconsistent for effector alleles between exposure and outcome data. If only one SNP was ultimately included, we used the Wald ratio for MR estimates, owing to its efficacy in providing accurate estimations in such contexts (Boehm and Zhou, 2022). When more than one SNP was available, inverse variance weighting (IVW) was used as main method. However, in scenarios where the data encompassed multiple SNPs, we utilized Cochran's Q test, a robust statistical tool, to evaluate the extent of heterogeneity among the SNPs. In instances where heterogeneity was identified, we adopted the random effects IVW model; conversely, if there was no evidence of heterogeneity, the fixed effects IVW model was our method of choice. The random effects IVW model is a commonly used method in MR analysis that accounts for the presence of heterogeneity by introducing random effects. Compared to fixed effects models, the random effects IVW model is more suitable for handling heterogeneity as it allows for differences between studies and assigns different weights to each study, thereby providing a more accurate estimation of the overall effect. According to the MR guidelines, IVW is deemed more effective than alternative methods in specific situations (Au Yeung and Gill, 2023). IVW, on the other hand, assumes that each genetic variant is a reliable tool, which may not always be the case in reality. Therefore, weighted median and MR Egger were used as supplementary methods to enhance the assessment of IVW. The MR Egger approach permits pleiotropic effects in all genetic variations, demanding that such effects are independent from the variant-exposure correlation. When less than half of the instrumental variables used in MR analysis are effective, the weighted median method permits the inclusion of ineffective instruments in evaluating causal effects. Finally, MR-PRESSO method was implemented for the identification and correction of outliers, ensuring the accuracy and reliability of our results.

In our primary MR analysis, a thorough evaluation was undertaken, which included an extensive examination of sixteen different outcomes, thereby providing a multifaceted perspective on the data under investigation. We employed the Bonferroni correction to address the issue of multiple testing, ensuring a more stringent and reliable determination of statistical significance. The Bonferroni correction is a commonly used method to control the error rate associated with multiple comparisons and reduce the risk of false positives. Specifically,

Outcome	Consortium	Population	Sample size	Sample case	Number of SNPs
FA-BMD	GEFOS	European	8,143	NA	9,955,366
LS-BMD	GEFOS	European	28,498	NA	10,582,867
FN-BMD	GEFOS	European	32,735	NA	10,586,900
eBMD	MRC-IEU	European	265,627	NA	9,851,867
TB-BMD	GEFOS	European	56,284	NA	16,162,733
TB-BMD (age over 60)	GEFOS	European	22,504	NA	11,932,096
TB-BMD (age 45-60)	GEFOS	European	18,805	NA	10,304,110
TB-BMD (age 30-45)	GEFOS	European	10,062	NA	9,656,698
TB-BMD (age 15-30)	GEFOS	European	4,180	NA	8,509,502
TB-BMD (age 0–15)	GEFOS	European	11,807	NA	9,351,693
AF	MRC-IEU	European	460,340	455,626	9,851,867
SF	MRC-IEU	European	460,340	459,304	9,851,867
LF	MRC-IEU	European	460,340	457,352	9,851,867
HF	MRC-IEU	European	306,379	NA	9,851,867
OPF	FinnGen	European	173,619	172,834	16,380,281
OP	FinnGen	European	212,778	209,575	16,380,452

TABLE 2 The detailed data information for outcomes.

FA-BMD, forearm bone mineral density; LS-BMD, lumbar spine bone mineral density; FN-BMD, femur neck bone mineral density; eBMD, heel bone mineral density; TB-BMD, total body bone mineral density; AF, arm fractures; SF, spine fractures; LF, leg fractures; HF, heel fractures; OPF, osteoporosis fracture; OP, osteoporosis; GEFOS, the Genetic Factors for osteoporosis Consortium; MRC-IEU, the Medical Research Council Integrative Epidemiology Unit.

we chose a threshold of p < 0.003 as the significance threshold. This threshold was determined by dividing 0.05 by the total number of outcomes. The *p*-values lower than 0.05 but not meeting the threshold for multiple-testing significance are considered as suggestive evidence of correlation. R software version 4.2.2 was used to perform the MR analysis using the TwoSampleMR (version 0.5.6) package.

3 Results

3.1 Selection of instrumental variables

Detailed information about the instrumental variables is presented in Table 3. The range of R^2 for circulating absolute antioxidants was 1.7%–30.1% (all *F*-statistics > 10), and the range of R^2 for circulating antioxidant metabolites was 6.8%–21.7% (all *F*-statistics > 10). All SNPs for instrumental variables are listed in Supplementary Tables S2 and S3. None of the included SNPs were significantly correlated with confounders (Supplementary Table S4).

3.2 Absolute circulating antioxidants and osteoporosis

The primary MR results concerning absolute antioxidants are illustrated in the forest plot of Figure 2. Cochran's Q statistic results suggested the presence of six heterogeneities, ascorbate in LS-BMD, FN-BMD, eBMD, TB-BMD and TB-BMD (age 0–15) and lycopene

in eBMD. Heterogeneity may arise due to methodological between studies, differences in differences population characteristics, variations in the effects of genetic variants, among other factors. To enhance statistical power, we employed the random effects IVW method as the primary MR analysis approach. Based on the primary MR analysis method, we identified three causal relationships, including two suggestive associations and one significant association. We provide strong evidence of a positive correlation between retinol levels and eBMD (p = 7.6E-05), with a unit change in retinol levels leading to a 28% increase in eBMD (OR: 1.28, 95% CI: 1.13-1.44). Given the significant genetic influence on eBMD (Kim, 2018) and the potential impact of sex on the physiological effects of circulating antioxidants, we respectively downloaded the male and female sections of the eBMD GWAS data for further analysis. In a subgroup analysis of eBMD by sex, we found that circulating levels of retinol were significantly associated with increased eBMD in men, but not in women (Figure 3). Moreover, we found a negative correlation between ascorbate levels and TB-BMD (age over 60) (p = 0.029)and a positive correlation between β-carotene levels and LS-BMD (p = 0.026), but it should be noted that these evidences are quite weak. Regarding the other traits, no potential causal links were observed.

For ascorbate and lycopene, the *p*-values of the MR Egger intercept test ranged from 0.095 to 0.978, indicating no pleiotropy (Supplementary Table S5). Due to the limited number of SNPs available, sensitivity analyses for β -carotene and retinol could not be conducted. In addition, utilizing supplementary MR analysis methods, we found no association between ascorbate levels

Trait	Sample size	p	LD	No.SNPs	Explained variance (R2, %)	Unit	Population	PMID
Absolute circ	culating antio	oxidants						
Ascorbate	52,018	5×10^{-8}	0.001	10	1.7	µmol/L	European	33,203,707
Lycopene	441	$5 imes 10^{-6}$	0.001	5	30.1	µg/dL	Amish	26,861,389
Retinol	5,006	$5 imes 10^{-8}$	0.001	2	2.3	μg/L in ln-transformed scale	Caucasian	21,878,437
β-Carotene	2,344	5×10^{-8}	0.001	1	4.8	μg/L in ln-transformed scale	European	23,134,893
Circulating a	ntioxidant m	netabolite	S					
α- Tocopherol	7,725	1×10^{-5}	0.001	11	6.8	log10-transformed metabolites concentration	European	24,816,252
γ- Tocopherol	6,226	1×10^{-5}	0.001	13	9.8	log10-transformed metabolites concentration	European	24,816,252
Ascorbate	2085	1×10^{-5}	0.001	14	21.7	log10-transformed metabolites concentration	European	24,816,252
Retinol	1960	1×10^{-5}	0.001	26	20.6	log10-transformed metabolites concentration	European	28,263,315

TABLE 3 The summary of instrumental variables for circulating antioxidants.

and TB-BMD (age over 60) (Supplementary Table S6). Interestingly, the weighted median results revealed a significant negative correlation between ascorbate levels and eBMD (p = 0.001). However, after the elimination of outliers using the MR PRESSO method, there was no significant association found between the two (p = 0.471), suggesting potential bias caused by outliers.

3.3 Circulating antioxidant metabolites and osteoporosis

The primary MR results regarding antioxidant metabolites are depicted in the forest plot of Figure 4. Cochran's Q statistic results also suggested the presence of five heterogeneities, α tocopherol in eBMD, γ -tocopherol in eBMD and LF, ascorbate in eBMD, and retinol in eBMD and TB-BMD. In the MR analysis of circulating antioxidant metabolites, we did not find evidence of significant associations. However, we identified five suggestive correlation evidences: α -tocopherol levels positively correlated with TB-BMD (age 45–60), ascorbate levels negatively correlated with TB-BMD and TB-BMD (age 0–15), retinol levels positively correlated with FA-BMD, and negatively with SF (OR = 0.999). As earlier mentioned, these pieces of evidence are weak.

In the MR Egger intercept test for circulating antioxidant metabolites, we found potential pleiotropy for α -tocopherol in TB-BMD (p = 0.049) (Supplementary Table S7). However, the MR PRESSO did not identify any outliers affecting this causal relationship assessment (Supplementary Table S8). In the supplementary MR analysis, there was no evidence to further support the suggestive associations. In the assessment of the causal relationship between four types of circulating antioxidant metabolites and eBMD, MR PRESSO identified outliers in each case. However, the MR analysis results after outlier removal were consistent with the primary MR analysis results.

4 Discussion

With the significant increase in the incidence of OP over the past few decades, it has become increasingly important to recognize modifiable risk factors, particularly dietary factors, as a promising strategy to curb the occurrence and progression of these diseases. Building on this understanding, in this study, we used genetic variations in the concentration of antioxidants as instrumental variables for exposure. Expanding the scope of our research, our outcome data encompasses not just OP and OPF, but also BMD across different body areas and age groups, along with fractures in various body locations. In terms of specific findings, our results demonstrate a notable positive association between absolute levels of retinol and eBMD. Interestingly, we also found that this significant causal relationship was related to gender. Additionally, we identified weak causal relationships of absolute ascorbate in TB-BMD (age over 60), β-carotene in LS-BMD, α-tocopherol in TB-BMD (age 45-60), relative ascorbate in TB-BMD and TB-BMD (age 0-15), and relative retinol in FA-BMD and SF. However, there was no evidence to support a causal relationship between other circulating antioxidants and the outcomes.

The relationships between antioxidants and the risk of OP have been evaluated in a number of observational studies. Yet, the question of whether antioxidants can mitigate the risk of OP remains debated. While some epidemiological research indicates that high levels of vitamin A (retinol) intake or serum vitamin A are linked to a negative impact on bone mass, this is not a universally accepted finding. Other studies contradict these findings, with some researchers suggesting that vitamin A may actually enhance bone health. For instance, an epidemiological study from Norway demonstrated that elevated serum vitamin A levels did not lead to a higher incidence of hip fractures (Holvik et al., 2015). In contrast, a meta-analysis by Wu et al. (Wu et al., 2014), encompassing eight studies on vitamin A intake, revealed a correlation between high vitamin A consumption and an increased risk of hip fractures. Similarly, a meta-

FA-BMD	No.SNPs	Heterogeneity	P	Method	OR (95% CI)		Ρ
	7	19 54%	0.281	Fixed effects IV/W	0.97 (0.77 to 1.23)		0.80
S-DMD	7	70.22%	0.002	Pandom offects IVA	M 0.97 (0.76 to 1.25)		0.00
	7	72 57%	0.001	Random offects IVA	N 0.02 (0.74 to 1.16)		0.50
DND	0	13.51%	0.001	Random effects IV	V 0.93 (0.74 (0 1.16)		0.50
BMD	9	86.80%	3.5E-10	Random effects IVV	/V 0.97 (0.90 to 1.05)		0.45
B-BMD	9	59.21%	0.012	Random effects IVV	W 0.96 (0.87 to 1.05)		0.37
B-BMD (age over 60)	9	39.49%	0.104	Fixed effects IVW	0.89 (0.80 to 0.99)		0.02
B-BMD (age 45-60)	9	0.00%	0.474	Fixed effects IVW	0.98 (0.87 to 1.10)		0.68
B-BMD (age 30-45)	9	37.76%	0.117	Fixed effects IVW	1.10 (0.94 to 1.29)	+ • ••	0.23
B-BMD (age 15-30)	9	0.00%	0.658	Fixed effects IVW	0.92 (0.73 to 1.18)		0.52
B-BMD (age 0-15)	9	54.49%	0.025	Random effects IVA	N 0.87 (0.70 to 1.09)		0.22
F	8	40.41%	0.109	Fixed effects IVW	1.00 (1.00 to 1.00)		0.70
	2	0.00%	0.462	Eixed offects IV/M	1.00 (1.00 to 1.00)		0.27
n C	3	0.0076	0.402	Fixed effects IVVV	1.00 (1.00 to 1.00)	1	0.37
F	/	50.91%	0.057	Fixed effects IVVV	1.00 (1.00 to 1.00)	1	0.49
11-	9	14.91%	0.310	Fixed effects IVW	1.00 (1.00 to 1.00)	•	0.14
DPF	8	38.33%	0.124	Fixed effects IVW	1.07 (0.55 to 2.06)	· · · · · · · · · · · · · · · · · · ·	0.84
)P	8	33.45%	0.161	Fixed effects IVW	0.86 (0.62 to 1.19)		0.35
						5 10 15 20	25
-carotene				535 AN 0 201	U.	5 1.0 1.5 2.0	2.5
Dutcome	No.SNI	Ps Heteroger	neity	Method Ol	R (95% CI)		P
		12	P				
	4			10/ald antia di	04 (0.05 to 4.07)		0.70
A-DIVID	1	-	-	vvaid ratio 1.	U4 (U.03 t0 1.27)		0.72
S-BMD	1	-	-	Wald ratio 1.	14 (1.02 to 1.28)		0.02
N-BMD	1	-	-	Wald ratio 1.	07 (0.97 to 1.18)		0.17
BMD	1	-	-	Wald ratio 1	01 (0.97 to 1 04)		0.74
P_PMD	1	-		Wold anti-	06 (0 08 to 1 14)	in the second seco	0.40
D-DIVID	1	-	-	vvaio ratio 1.	00 (0.90 to 1.14)	1	0.13
B-BMD (age over 60	J) 1	-	-	Wald ratio 1.	11 (0.97 to 1.26)		0.13
B-BMD (age 45-60)) 1	-	-	Wald ratio 1.	02 (0.89 to 1.18)		0.74
B-BMD (age 30-45)	1	-	-	Wald ratio 0	98 (0.81 to 1.21)		0.88
D DMD (age 00 40)				Wald ratio 0.	10 (0.00 1: 1.50)		0.00
B-BMD (age 15-30)) 1	1.0	-	vvaid ratio 1.	13 (0.83 to 1.56)		0.43
TB-BMD (age 0-15)	1	-	-	Wald ratio 1.	00 (0.85 to 1.19)		0.96
٩F	1	-	-	Wald ratio 1.	00 (1.00 to 1.00)	•	0.35
2F	1	-		Wald ratio 1	00 (1 00 to 1 00)	1	0.18
-				valuratio 1.	00 (1.00 10 1.00)	1	0.10
.F	1		-	Wald ratio 1.	00 (1.00 to 1.00)		0.70
ΗF	1	-	-	Wald ratio 1.	00 (1.00 to 1.00)	•	0.08
OPF	1	-	-	Wald ratio 0.0	64 (0.32 to 1.30)		0.21
np	1	-		Wald ratio 1	30 (0 92 to 1 85)		0.14
51				Thata Tatlo			
ycopene		Hotorogonolity		Mothod	0.5	1.0 1.5	2.0
Jucome	NU.ONFS	Heterogeneity		wethou	OK (55% CI)		
		P-	P				
A-BMD	3	0.00%	0.414	Fixed effects IVW	1.03 (0.96 to 1.12)		0.37
.S-BMD	3	0.00%	0.530	Fixed effects IVW	1.03 (0.98 to 1.07)		0.20
N-BMD	3	0.00%	0.788	Fixed effects IVW	1.00 (0.97 to 1.04)		0.87
BMD	4	67.22%	0.027	Random effects IVN	N 1.00 (0.98 to 1.02)	H H H	0.77
B-BMD	4	0.00%	0.765	Fixed effects IVW	0.99 (0.96 to 1.02)	1-0-1	0.54
B-BMD (age over 60)	4	0.00%	0.505	Fixed effects IV/W	0.99 (0.94 to 1.03)		0.54
P-PMD (ago 4E-60)		0.00%	0.047	Eived offects N/M	0.07 (0.02 to 1.02)		0.26
B-BMD (age 45-00)		0.00%	0.947	Fixed effects IVVV	0.97 (0.92 (0 1.02)		0.20
B-BMD (age 30-45)	4	20.43%	0.287	Fixed effects IVVV	1.02 (0.95 to 1.09)		0.60
B-BMD (age 15-30)	4	0.00%	0.965	Fixed effects IVW	0.99 (0.88 to 1.12)		0.87
B-BMD (age 0-15)	4	0.00%	0.549	Fixed effects IVW	1.01 (0.95 to 1.08)		0.66
NF .	1	-	-	Wald ratio	1.00 (1.00 to 1.00)	•	0.53
F	0	-	-	-	-		
F	1	-		Wald ratio	1.00 (1.00 to 1.00)	1	0.11
	:	0.000/	0.400	Final affects Patt	1.00 (1.00 to 1.00)	I	0.11
10	4	0.00%	0.429	Fixed effects IVW	1.00 (1.00 to 1.00)	•	0.94
	4	0.00%	0.857	Fixed effects IVW	1.14 (0.89 to 1.45)	-	→0.30
JPF	4	41.10%	0.165	Fixed effects IVW	1.10 (0.97 to 1.24)	•	0.13
)P					0	8 09 10 11	12
PP Petinol	No CNDo	Heterogeneity		Method	OR (95% CI)	0 0.0 1.0 1.1	P
etinol Jutcome	NO.ONES	12	P				
etinol Outcome	NO.3NFS			Eined offects DAM			0.471
etinol Outcome	2	32 59%	0.2.2.4	Property of the second second	1 31 (0 63 to 2 74)		0.700
PPP etinol Dutcome SA-BMD S-BMD	2	32.59%	0.223	Fixed effects IVVV	1.31 (0.63 to 2.74)		
etinol Dutcome A-BMD S-BMD	2 2	32.59% 0.00%	0.223	Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62)	•	0.732
PP etinol Dutcome A-BMD S-BMD	2 2 2	32.59% 0.00% 0.00%	0.223 0.643 0.934	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59)	••••	0.540
A-BMD S-BMD N-BMD BMD	2 2 2 2 2	32.59% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975	Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44)		0.540 7.6E-0
A-BMD S-BMD NN-BMD B-BMD B-BMD B-BMD	2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637	Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27)		0.732 0.540 7.6E-0 0.831
A-BMD S-BMD S-BMD N-BMD B-BMD B-BMD B-BMD (age over 60)	2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518	Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69)		0.732 0.540 7.6E-0 0.831 0.788
A-BMD S-BMD N-BMD B-BMD B-BMD B-BMD (age over 60) B-BMD (age 45-60)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00% 36.9%	0.223 0.643 0.934 0.975 0.637 0.518 0.208	Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69) 0.83 (0.50 to 1.38)		0.732 0.540 7.6E-0 0.831 0.788 0.486
P stinol hutcome A-BMD S-BMD BMD B-BMD B-BMD (age over 60) B-BMD (age 345-60) B-BMD (age 345-60)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304	Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69) 0.83 (0.50 to 1.38) I.67 (0.83 to 3.36)		0.732 0.540 7.6E-0 0.831 0.788 0.486
PP btinol tutcome A-BMD S-BMD BMD B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 30-45)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) ► 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69) ► 0.83 (0.50 to 1.38) ► 1.67 (0.83 to 3.36) 1.07 (0.37 to 3.45) ►		0.732 0.540 7.6E-0 0.831 0.788 0.486 → 0.154 → 0.995
PP btinol lutcome A-BMD S-BMD BMD B-BMD (age over 60) B-BMD (age over 60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 15-30)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69) 0.83 (0.50 to 1.38) 1.67 (0.83 to 3.36) 1.07 (0.37 to 3.15) 		0.732 0.540 7.6E-0 0.831 0.788 0.486 → 0.154 → 0.895
A-BMD A-BMD S-BMD BMD B-BMD B-BMD (age over 60) B-BMD (age 30-45) B-BMD (age 0-15)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00% 5.35% 46.13% 23.33%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) ► 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.06 (0.67 to 1.69) 0.83 (0.50 to 1.38) ► 1.67 (0.83 to 3.36) 1.07 (0.37 to 3.15) ← 0.84 (0.46 to 1.55) ←		0.732 0.540 7.6E-0 0.831 0.788 0.486 → 0.154 → 0.895 0.585
PP stinol Jutcome S-BMD S-BMD B-BMD B-BMD (age 45-60) B-BMD (age 5-60) B-BMD (age 5-60) B-BMD (age 6-15)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13% 23.33% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482	Fixed effects I/W Fixed effects I/W	1.31 (0.63 to 2.74) ► 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.27) 1.66 (0.67 to 1.69) □ 0.83 (0.50 to 1.38) → 1.67 (0.83 to 3.36) 1.07 (0.37 to 3.15) ← 0.84 (0.46 to 1.55) ← 0.99 (0.98 to 1.00)		0.732 0.540 7.6E-0 0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.155
PP stinol A-BMD S-BMD BMD B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 45-60) B-BMD (age 45-61) B-BMD (age 46-61) B-BMD (age 46-61)	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 5.35% 46.13% 23.33% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) + 1.07 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.37 (0.74 to 1.27) 1.06 (0.67 to 1.69) + 0.63 (0.50 to 1.38) + 1.67 (0.83 to 3.36) 1.07 (0.37 to 3.15) + 0.84 (0.46 to 1.55) + 0.99 (0.98 to 1.00) 1.00 (1.00 to 1.00)		0.732 0.540 7.6E−0 0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.155 0.888
PP stinol >butcome S-BMD S-BMD B-BMD B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 0-15) F F	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13% 23.33% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417 0.643	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) = 1.31 (0.63 to 2.74) = 1.12 (0.78 to 1.62) 1.28 (1.13 to 1.44) 0.97 (0.74 to 1.59) = 0.83 (0.50 to 1.89) = 1.07 (0.83 to 3.36) = 1.07 (0.37 to 3.15) = 0.84 (0.46 to 1.55) = 0.99 (0.98 to 1.00) 1.00 (0.99 to 1.01)		0.732 0.540 7.6E-0 0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.155 0.888 0.755
A-BMD S-BMD S-BMD B-BMD B-BMD (age over 60) B-BMD (age 50-61) B-BMD (age 50-61) B-BMD (age 50-61) B-BMD (age 0-15) F F F F F F F F F F F	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 5.35% 46.13% 23.33% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417 0.643 0.615	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) ► 1.17 (0.71 to 1.62) 1.12 (0.78 to 1.59) 1.28 (1.13 to 1.44) 0.57 (0.74 to 1.27) 1.06 (0.67 to 1.69) 0.63 (0.50 to 1.38) 1.07 (0.37 to 3.36) 1.07 (0.37 to 3.36) 1.07 (0.37 to 3.15) ← 0.84 (0.46 to 1.55) 0.99 (0.98 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.01 (1.00 to 1.01)		0.752 0.540 7.6E-(0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.155 0.888 0.755 0.102
PFP stinol sticone A-BMD S-BMD N-MMD B-MMD (age over 60) B-BMD (age over 60) B-BMD (age 0-15) F F F F F F F F F F F F F F F	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13% 23.33% 0.00% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417 0.643 0.643 0.288	Fixed effects IVW Fixed effects IVW	$\begin{array}{c} 1.31 (0.63 \text{ to } 2.74) \\ = \\ 1.07 (0.71 \text{ to } 1.62) \\ 1.12 (0.78 \text{ to } 1.52) \\ 1.28 (1.13 \text{ to } 1.44) \\ 0.97 (0.74 \text{ to } 1.27) \\ 1.06 (0.67 \text{ to } 1.89) \\ 0.33 (0.50 \text{ to } 1.38) \\ - \\ 1.07 (0.37 \text{ to } 3.16) \\ - \\ 0.48 (0.46 \text{ to } 1.55) \\ - \\ 0.99 (0.98 \text{ to } 1.00) \\ 1.00 (1.00 \text{ to } 1.00) \\ 1.00 (1.00 \text{ to } 1.00) \\ 1.00 (1.00 \text{ to } 1.01) \\ 1.01 (1.00 \text{ to } 1.01) \\ 1.01 (1.00 \text{ to } 1.01) \\ 1.31 (0.10 \text{ to } 5.67) \\ - \\ \end{array}$		0.732 0.540 7.6E−0 0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.585 0.885 0.755 0.888 0.755 0.888 0.755 0.885 0.782
PP etinol A-BMO S-BMO N-BMD B-BMO B-BMO Rege 5-60 B-BMO (age 5-60) B-BMO (age 30-45) B-BMO (age 30-45) B-BMO (age 0-15) F F F F F F F F F F F F F	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 0.00% 5.35% 46.13% 23.33% 0.00% 0.00% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.975 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417 0.643 0.645 0.265	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) 1.12 (0.78 to 1.52) 1.12 (0.78 to 1.59) 1.12 (0.78 to 1.59) 1.12 (0.78 to 1.59) 1.05 (0.67 to 1.69) 0.83 (0.50 to 1.69) 1.67 (0.83 to 3.36) 1.67 (0.83 to 3.36) 1.67 (0.83 to 3.36) 1.67 (0.83 to 3.36) 1.67 (0.98 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.01 (1.00 to 1.01) 1.31 (0.10 to 1.61, 99) 4.67 (0.10 to 1.63, 99) 4.67		0.752 0.540 7.6E−0 0.831 0.788 0.486 → 0.154 → 0.895 0.585 0.155 0.888 0.755 0.102 → 0.827 0.102
P stinol stinol vutcome s-BMD s-BMD B-BMD (sge over 60) B-BMD (sge over 60) B-BMD (sge 0-45) B-BMD (sge 0-15) F	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	32.59% 0.00% 0.00% 0.00% 0.00% 36.9% 5.35% 46.13% 23.33% 0.00% 0.00% 0.00% 0.00% 0.00%	0.223 0.643 0.934 0.934 0.935 0.637 0.518 0.208 0.304 0.173 0.253 0.482 0.417 0.643 0.615 0.268 0.561	Fixed effects IVW Fixed effects IVW	1.31 (0.63 to 2.74) = 1.12 (0.78 to 1.62) 1.12 (0.78 to 1.62) 1.12 (0.78 to 1.59) 1.12 (0.78 to 1.59) 0.83 (0.50 to 1.28) = 1.67 (0.83 to 3.36) 1.67 (0.83 to 3.36) 1.67 (0.83 to 3.36) 0.84 (0.46 to 1.55) 0.99 (0.98 to 1.00) 1.00 (1.90 to 1.00) 1.00 (1.90 to 1.01) 1.01 (1.00 to 1.01) 1.31 (0.10 to 16.29) 0.44 (0.16 to 2.30) 4.40 (1.50 to 3.30) 1.50 (1.50 to 3.50) 1.50 (1.50 to 3.5		0.732 0.540 7.6E−0 0.831 0.788 0.486 0.154 0.585 0.155 0.888 0.755 0.102 0.837 0.496

circulating antioxidant levels on osteoporosis. Results with *p* less than 0.05 highlighted in bold. "-" represents not applicable.

analysis by Zhang et al. (Zhang et al., 2017a), involving 13 studies, showed that increased vitamin A intake was linked to a lower risk of fractures at various sites, but with a notable increase in the risk of hip

fractures. However, another piece of research reported an increase in BMD levels with higher vitamin A intake, leading to conflicting conclusions (Barker et al., 2005). In the context of our MR study, absolute retinol levels were significantly positively correlated with eBMD in men. In addition, there were suggestive associations found between metabolic levels of retinol and increased FA-BMD (OR = 1.041, p = 0.042) and decreased risk of SF (OR = 0.999, p = 0.049). Those with OP may benefit from a diet rich in antioxidants, especially vitamin A, and an antioxidant-preserving lifestyle. Vitamin A exerts its effects through the metabolite all-trans-retinoic acid (ATRA), a potent transcriptional regulator that modulates the expression of genes crucial for mediating the indirect antioxidant properties of vitamin A. Consequently, vitamin A can activate the NRF2/KEAP1 or NF-кB signaling pathways to mitigate oxidative stress and decrease the risk of OP (Dinkova-Kostova and Talalay, 2008; Abraham et al., 2019). However, larger clinical trials are needed to increase the credibility of clinical recommendations, especially given the presence of weak causality and sex-specific effects of retinol.

As a key antioxidant, Vitamin C (ascorbate) plays a crucial role in removing ROS, thereby reducing oxidative stress (Kim and Lee, 2016). Vitamin C has been shown to stimulate the formation of osteoclasts and osteoblasts in vitro, although high doses of the vitamin can also exhibit cytotoxic effects on both cell types (Chin and Ima-Nirwana, 2018). New et al. discovered a non-linear relationship between vitamin C consumption and BMD in a of 994 healthy premenopausal cohort women aged 45-49 participating in the Osteoporosis Screening Program in Aberdeen (New et al., 1997). According to a report conducted by Kim and Lee (Kim and Lee, 2016), an elevated intake of vitamin C may decrease the likelihood of OP among Korean adults over 50 who have low levels of physical activity, but surprisingly, this benefit does not extend to those with higher levels of physical activity. Moreover, increased dietary intake of vitamin C has been linked to a decreased risk of hip fractures and OP, as well as to enhanced BMD, notably in the femoral neck and lumbar spine areas (Malmir et al., 2018). Simon and colleagues discovered a significant nonlinear relationship between serum vitamin C levels and hip BMD in men (Simon and Hudes, 2001). Specifically, hip BMD initially increased with rising serum vitamin C levels, but subsequently decreased as serum vitamin C levels continued to rise. Interestingly, while primarily known for its antioxidant effects, vitamin C can display prooxidant characteristics at high doses, as indicated by a previous study where a daily supplementation of 500 mg of vitamin C in individuals aged 17 to 49 for 6 weeks led to oxidative DNA damage (Podmore et al., 1998), a factor potentially relevant to OP (Finck et al., 2014). The current study identified three



FA-BMD -S-BMD -N-BMD -BMD -BMD -B-BMD	No.SNPs					
A-BMD S-BMD N-BMD BMD B-BMD		Heterogeneity		Method	OR (95% CI)	P
A-BMD S-BMD N-BMD BMD B-BMD		12	P			
S-BMD N-BMD BMD B-BMD	9	0.00%	0.761	Fixed effects IVW	1.00 (0.56 to 1.79)	0.9
N-BMD BMD B-BMD	8	0.00%	0.892	Fixed effects IVW	1.35 (0.96 to 1.89)	• 0.0
BMD B-BMD	8	0.00%	0.501	Fixed effects IV/W	1 10 (0.82 to 1.48)	0.5
B-BMD	0	71 99%	4 OF 10	Pandom offects IVAV	1.08 (0.00 to 1.20)	0.0
B-BMD	9	71.00%	4.02-10	Random elects IVVV	1.00 (0.00 to 1.20)	0.4
	9	23.15%	0.237	Fixed effects IVVV	1.10 (0.89 to 1.35)	- 0.3
B-BMD (age over 60)	9	0.00%	0.904	Fixed effects IVW	1.00 (0.70 to 1.42)	- 0.95
B-BMD (age 45-60)	9	1.06%	0.425	Fixed effects IVW	1.55 (1.04 to 2.32)	• 0.03
B-BMD (age 30-45)	9	38.51%	0.112	Fixed effects IVW	1.41 (0.82 to 2.42)	• 0.2
B-BMD (age 15-30)	9	0.00%	0.685	Fixed effects IVW	1.65 (0.72 to 3.75)	→0.2 ²
B-BMD (age 0-15)	9	0.00%	0.523	Fixed effects IVW	0.73 (0.46 to 1.17)	0.1
F	4	19.97%	0.290	Fixed effects IVW	1.00 (0.99 to 1.02)	0.43
F	1	-	-	Weld ratio	0.99 (0.97 to 1.00)	0.1
-	2	0.00%	0.677	Elucid effects DAM	1.01 (0.00 to 1.00)	0.1
.F	3	0.00%	0.077	Fixed effects IVVV	1.01 (0.99 (0 1.02)	0.2
r	9	23.70%	0.233	Fixed effects IVVV	1.00 (1.00 to 1.01)	0.2
PF	9	0.00%	0.529	Fixed effects IVW	1.90 (0.30 to 12.24)	→0.49
)P	9	36.05%	0.130	Fixed effects IVW	2.05 (0.81 to 5.20)	→ 0.13
toconherol					0.5 1.0	15 20 25
locopileioi	No CNDo	Hotorogeneity		Mathed	OB (05% CI)	1.0 2.0 2.0
utcome	NO.5NPS	Heterogeneity		Method	OR (95% CI)	٢
		²	P			
A-BMD	13	0.00%	0.589	Fixed effects IVW	1.13 (0.99 to 1.30)	
S-BMD	13	0.00%	0.962	Fixed effects IVW	1.04 (0.96 to 1.12)	0.36
N-BMD	13	0.00%	0.991	Fixed effects IVW	1.04 (0.97 to 1.12)	0.2
PMD	12	49 210/	0.020	Random offerte hat	0.00 (0.00 to 1.12)	0.2
DWD	13	40.21%	0.026	Random effects IVW	0.99 (0.96 to 1.02)	0.7
R-RWD	13	0.00%	0.844	Fixed effects IVW	1.00 (0.95 to 1.05)	0.93
B-BMD (age over 60)	13	0.00%	0.909	Fixed effects IVW	0.99 (0.90 to 1.07)	• 0.75
B-BMD (age 45-60)	13	8.17%	0.364	Fixed effects IVW	1.00 (0.91 to 1.10)	0.9
B-BMD (age 30-45)	13	0.00%	0.822	Fixed effects IVW	1.07 (0.94 to 1.22)	→ 0.3
B-BMD (age 15-20)	12	29.159/	0.161	Fixed effects IV/W	0.08 (0.81 to 1.10)	
B-BWD (age 15-50)	13	20.1370	0.101	Fixed effects IVVV	0.98 (0.81 (0 1.19)	0.0
B-BMD (age 0-15)	13	0.00%	0.593	Fixed effects IVW	0.95 (0.85 to 1.07)	0.4
F	9	1.37%	0.423	Fixed effects IVW	1.00 (1.00 to 1.00)	· 0.25
F	6	42.56%	0.121	Fixed effects IVW	1.00 (1.00 to 1.00)	0.6
F	9	48.80%	0.048	Random effects IVW	1.00 (1.00 to 1.00)	0.8
IF.	13	14.08%	0.303	Eived affects IV/M	1.00 (1.00 to 1.00)	0.70
	10	14.00%	0.000	Tixed effects IVVV	1.00 (1.00 to 1.00)	0.1
	13	11.50%	0.330	Fixed effects IVVV	0.69 (0.42 to 1.13)	0.14
OP	13	0.00%	0.452	Fixed effects IVW	1.00 (0.78 to 1.27)	<u> </u>
scorbate					08 09	10 11 12
Duteeme		Hotorogonoity		Mathed	OR (85% CI)	1.0 1.1 1.2
Jucome	NU.ONFS	Heterogeneity	-	Wethou	OR (55% CI)	F
		ls.	Р			
A-BMD	10	0.00%	0.875	Fixed effects IVW	1.11 (0.81 to 1.52)	- 0.50
S-BMD	9	23.41%	0.235	Fixed effects IVW	1.02 (0.85 to 1.23)	4 0.79
N-BMD	9	0.00%	0.479	Fixed effects IVW	0.99 (0.84 to 1.16)	0.86
BMD	11	68 72%	4.0F-10	Random effects IVW	1.08 (0.99 to 1.19)	0.00
D DMD		40 649/	0.000	Fixed effects DAM	0.87 (0.78 to 0.07)	0.00
		42.5170	0.000	Fixed effects IVVV	0.07 (0.76 to 0.37)	0.0
B-BIND (age over 60)	11	0.00%	0.773	Fixed effects IVVV	0.86 (0.71 to 1.03)	0.10
B-BMD (age 45-60)	11	15.17%	0.299	Fixed effects IVW	0.93 (0.75 to 1.16)	0.53
B-BMD (age 30-45)	11	23.63%	0.218	Fixed effects IVW	0.94 (0.70 to 1.26)	- 0.6
B-BMD (age 15-30)	11	28.04%	0.178	Fixed effects IVW	0.95 (0.61 to 1.49)	0.8
B-BMD (age 0-15)	11	33 21%	0.133	Fixed effects IVW	0.72 (0.56 to 0.92)	0.00
E DIND (age o 10)	10	25.00%	0.100	Fixed effects IVW	1.00 (1.00 to 1.00)	0.00
	0	0.0070	0.121	Fixed effects IVW	1.00 (1.00 to 1.00)	0.8
ot-	3	0.00%	0.869	Fixed effects IVW	1.00 (0.99 to 1.00)	0.22
F	10	0.00%	0.858	Fixed effects IVW	1.00 (1.00 to 1.01)	0.06
IF	11	2.73%	0.416	Fixed effects IVW	1.00 (0.99 to 1.00)	0.23
OPF	11	40.34%	0.080	Fixed effects IVW	2.36 (0.88 to 6.32)	••0.0
P	11	26 12%	0.195	Fixed effects IV/W	1 32 (0 81 to 2 16)	0.20
		20.1270	0.155	Fixed effects IVVV	1.52 (0.61 (0 2.10)	0.20
etinol					0.5 1.0	1.5 2.0 2.5
Dutcome	No.SNPs	Heterogeneity		Method	OR (95% CI)	P
		12	P			
A-BMD	21	10 96%	0.202	Eived offects IV/A	1.04 (1.00 to 1.08)	
A-DMD	41	18.00%	0.203	Fixed effects IVVV	1.04 (1.00 to 1.00)	0.04
S-RWD	18	27.59%	0.134	Fixed effects IVW	1.00 (0.97 to 1.02)	··•• 0.93
N-BMD	18	0.00%	0.587	Fixed effects IVW	1.00 (0.98 to 1.02)	••• 0.90
BMD	20	47.06%	0.011	Random effects IVW	1.00 (0.99 to 1.00)	• 0.3
B-BMD	23	35.61%	0.047	Random effects IV/W	0.99 (0.97 to 1.01)	0.00
	22	0.65%	0.200	Eined offects 0.04	1.00 (0.07 to 1.01)	0.20
P-PMD (acc	23	0.00%	0.329	Fixed enects IVVV	1.00 (0.97 to 1.02)	0.89
B-BMD (age over 60)	23	0.00%	0.703	Fixed effects IVW	0.99 (0.97 to 1.02)	0.59
B-BMD (age over 60) B-BMD (age 45-60)	22	23.81%	0.153	Fixed effects IVW	1.00 (0.96 to 1.04)	0.99
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45)	21	0.00%	0.547	Fixed effects IVW	1.03 (0.97 to 1.09)	0.3
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30)		8 08%	0.342	Fixed effects IV/M	0.97 (0.94 to 1.00)	0.0
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15)	21	0.00%	0.342	Fixed effects IVVV	0.67 (0.94 (0 1.00)	0.08
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15)	21	011000	0.214	Fixed effects IVW	1.00 (1.00 to 1.00)	• 0.4
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15) F	21 11	24.12%			4 00 (4 00 1 4 00)	
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15) F F	21 11 3	24.12% 0.00%	0.570	Fixed effects IVW	1.00 (1.00 to 1.00)	0.0
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15) JF F	21 11 3 10	24.12% 0.00% 0.00%	0.570	Fixed effects IVW Fixed effects IVW	1.00 (1.00 to 1.00)	0.5
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15) JF F F	21 11 3 10	24.12% 0.00% 0.00%	0.570	Fixed effects IVW Fixed effects IVW	1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)	0.56
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 15-30) F F F F IF	21 11 3 10 20	24.12% 0.00% 0.00% 0.00%	0.570 0.771 0.627	Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)	0.56 0.12
B-BMD (age over 60) B-BMD (age 45-60) B-BMD (age 30-45) B-BMD (age 15-30) B-BMD (age 0-15) F F F F IF IF	21 11 3 10 20 20	24.12% 0.00% 0.00% 0.00% 0.00%	0.570 0.771 0.627 0.488	Fixed effects IVW Fixed effects IVW Fixed effects IVW Fixed effects IVW	1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (0.86 to 1.15)	0.5t

The primary MR analyses results of the causal effects of circulating antioxidant metabolites on osteoporosis. Results with *p* less than 0.05 highlighted in bold. "-" represents not applicable.

suggestive causal associations between absolute ascorbate concentrations and reduced TB-BMD (age over 60) and metabolic concentrations of ascorbate with reduced TB-BMD and TB-BMD (age 0–15). However, higher-quality trials are necessary to determine if Vitamin C significantly reduces the risk of OP.

Vitamin E, known for its antioxidant properties, is divided into two primary subgroups, namely, tocopherols and tocotrienols. Each of these subgroups contains four unique analogs: alpha, beta, gamma, and delta (Zhang et al., 2017b). Significantly, α -tocopherol is one of the homologs within the vitamin E category. Research suggests that vitamin E may benefit bone health due to its anti-inflammatory properties, yet this effect has not been conclusively demonstrated in human subjects (Reid and New, 1997). To further explore this, Shi et al. (Shi et al., 2016) investigated the correlation between vitamin E levels and BMD in middle-aged and elderly adults (40–75 years) in Guangzhou, China. Their findings indicated a positive association between higher intake and serum levels of vitamin E and increased BMD in Chinese women. but this association was not mirrored in Chinese men. These results are similar to our findings, as our MR analysis revealed a suggestive association between the metabolic level of a-tocopherol and increased TB-BMD in individuals aged 45-60. In contrast, a negative correlation has been observed between serum a-tocopherol levels and femoral neck bone mineral density among the elderly population in the US (both men and women over 50), indicating a potentially detrimental impact of a-tocopherol on bone health (Zhang et al., 2017b). y-tocopherol, the second most prevalent isoform of vitamin E found in dietary sources, accounts for 20%-25% of total vitamin E intake and exhibits the ability to scavenge both reactive nitrogen species (RNS) and ROS, distinguishing it from a-tocopherol (Abraham et al., 2019). While a clinical trial indicated that supplementation with y-tocopherol reduces systemic oxidative stress, findings from cross-sectional studies have been inconclusive. Yang et al. (Yang et al., 2016) did not observe statistically significant associations between y-tocopherol and BMD in a study involving over 5,000 older women. In contrast, Ilesanmi-Oyelere et al. (Ilesanmi-Oyelere et al., 2019) reported that increased vitamin E intake was linked to lower BMD levels. The current body of evidence regarding the impact of ytocopherol on OP remains limited, highlighting the need for more rigorous trials to elucidate its effects.

Lycopene is an acyclic isomer derived from β-carotene (Agarwal and Rao, 2000). A long-term study over 17 years found that increased lycopene consumption was associated with a lower incidence of hip and nonvertebral fractures, highlighting its potential role in bone health (Sahni et al., 2009). This elevation in lycopene potentially lowers oxidative stress and bone resorption markers, thereby suggesting a possible reduction in the risk of OP. Nevertheless, a cross-sectional study involving 4,820 individuals in the United States revealed no significant association between lycopene intake and OP (Kan et al., 2021). There is weak evidence that β -carotene levels are associated with increased LS-BMD in the current study. However, the results of a previous MR performed by li et al. (Li et al., 2023) showed that serum β -carotene levels significantly reduced OP risk. For the instrumental variables of β-carotene, we used more strict screening criteria ($p < 5 \times 10^{-8}$ and $r^2 < 0.001$), which helped us to make more reliable conclusions. Furthermore, in our study, we also analyzed subgroups of TB-BMD according to age. In conclusion, the weak causal relationship between β carotene levels and increased LS-BMD provides some insight into the reduction of OP risk by dietary antioxidants.

The study we conducted possesses a range of strengths. Primarily, the MR approach, utilizing two separate samples, reduces the potential risks that participants may encounter in clinical trials. Additionally, the application of distinct sets of instrumental variables for both absolute circulating antioxidants and their metabolites increases the informative value of the MR study outcomes. However, our study does have its limitations. One of the primary limitations is the constrained number of SNPs for antioxidant instrumental variables that were sourced from published GWAS data. In other MR analysis, absolute retinol and β -carotene were also unable to validate the robustness of the results using complementary MR analysis methods due to limitations in the number of SNPs (Mondul et al., 2011; Hendrickson et al., 2012; Zhao et al., 2023). It should

be noted, however, that these SNPs are situated within essential genes pertinent to antioxidant metabolism, according to the PhenoScanner database (Kamat et al., 2019). In future studies, identifying more relevant loci through broader GWAS will be critical to strengthen the effectiveness of the instrumental variables. Another point is that antioxidant concentrations vary greatly with different detection methods, underscoring the need for standardizing these techniques in future studies. Finally, postmenopausal status was not included in the subgroup analyses due to data limitations, which may have weakened the reliability of our conclusions. Broader GWAS data are needed for more detailed subgroup analyses in the future.

5 Conclusion

In conclusion, there is a positive causal relationship between absolute retinol levels and eBMD. Our study, however, was unable to establish evidence of a causal relationship between retinol and BMD at other body sites or fractures. The implications of these results should be taken into account in future studies and in the creation of public health policies and OP prevention tactics.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

KY: Conceptualization, Writing-original draft. XX: Conceptualization, Funding acquisition, Writing-review and editing. WH: Data curation, Formal Analysis, Writing-review and editing. DL: Data curation, Formal Analysis, Writing-review and editing. YZ: Data curation, Formal Analysis, Writing-review and editing. HY: Data curation, Formal Analysis, Writing-review and editing. XW: Conceptualization, Writing-review and editing.

References

Abraham, A., Kattoor, A. J., Saldeen, T., and Mehta, J. L. (2019). Vitamin E and its anticancer effects. *Crit. Rev. food Sci. Nutr.* 59 (17), 2831–2838. Epub 2018/05/11. doi:10.1080/10408398.2018.1474169

Agarwal, S., and Rao, A. V. (2000). Tomato lycopene and its role in human health and chronic diseases. *CMAJ Can. Med. Assoc. J. = J. de l'Association medicale Can.* 163 (6), 739–744. Epub 2000/10/07.

Arceo-Mendoza, R. M., and Camacho, P. M. (2021). Postmenopausal osteoporosis: latest guidelines. *Endocrinol. metabolism Clin. N. Am.* 50 (2), 167–178. Epub 2021/05/ 24. doi:10.1016/j.ecl.2021.03.009

Au Yeung, S. L., and Gill, D. (2023). Standardizing the reporting of mendelian randomization studies. *BMC Med.* 21 (1), 187. Epub 2023/05/18. doi:10.1186/s12916-023-02894-8

Baek, K. H., Oh, K. W., Lee, W. Y., Lee, S. S., Kim, M. K., Kwon, H. S., et al. (2010). Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. *Calcif. tissue Int.* 87 (3), 226–235. Epub 2010/07/09. doi:10.1007/s00223-010-9393-9

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by National Natural Science Foundation of China (82160911, 82374491), the third batch of provincial science and technology programs in 2023 (Basic Research Program-Natural Science Foundation - Excellent Doctoral Program) (23JRRA1226), Gansu excellent graduate student innovation star project (2023CXZX-732); and Gansu Top Talents (Science and Technology Territory) Training Support Fund Project [(2021) No. 2].

Acknowledgments

The authors thank all investigators for sharing the GWAS summary data.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2024.1346367/ full#supplementary-material

Bai, W. Y., Wang, L., Ying, Z. M., Hu, B., Xu, L., Zhang, G. Q., et al. (2020). Identification of Piezo1 polymorphisms for human bone mineral density. *Bone* 133, 115247. Epub 2020/01/23. doi:10.1016/j.bone.2020.115247

Barker, M. E., McCloskey, E., Saha, S., Gossiel, F., Charlesworth, D., Powers, H. J., et al. (2005). Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women. *J. bone mineral Res. official J. Am. Soc. Bone Mineral Res.* 20 (6), 913–920. Epub 2005/05/11. doi:10.1359/jbmr.050112

Black, D. M., Geiger, E. J., Eastell, R., Vittinghoff, E., Li, B. H., Ryan, D. S., et al. (2020). Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. *N. Engl. J. Med.* 383 (8), 743–753. Epub 2020/08/20. doi:10. 1056/NEJM0a1916525

Boehm, F. J., and Zhou, X. (2022). Statistical methods for mendelian randomization in genome-wide association studies: a review. *Comput. Struct. Biotechnol. J.* 20, 2338–2351. Epub 2022/05/27. doi:10.1016/j.csbj.2022.05.015

Borgström, F., Karlsson, L., Ortsäter, G., Norton, N., Halbout, P., Cooper, C., et al. (2020). Fragility fractures in europe: burden, management and opportunities. *Archives Osteoporos.* 15 (1), 59. Epub 2020/04/20. doi:10.1007/s11657-020-0706-y

Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., et al. (2019). Guidelines for performing mendelian randomization investigations. *Wellcome open Res.* 4, 186. Epub 2020/08/11. doi:10.12688/wellcomeopenres.15555.2

Chen, R., Liu, H., Zhang, G., Zhang, Q., Hua, W., Zhang, L., et al. (2024). Antioxidants and the risk of stroke: results from nhanes and two-sample mendelian randomization study. *Eur. J. Med. Res.* 29 (1), 50. Epub 2024/01/13. doi:10.1186/s40001-024-01646-5

Chin, K. Y., and Ima-Nirwana, S. (2018). Vitamin C and bone health: evidence from cell, animal and human studies. *Curr. drug targets* 19 (5), 439–450. Epub 2015/09/08. doi:10.2174/1389450116666150907100838

Cui, J., Liu, H., Shao, J., Xu, D. M., Wang, Y., Fei, Z., et al. (2018). Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia. *Schizophrenia Res.* 195, 488–494. Epub 2017/10/24. doi:10.1016/j. schres.2017.10.027

D Adamo, C. R., D'Urso, A., Ryan, K. A., Yerges-Armstrong, L. M., Semba, R. D., Steinle, N. I., et al. (2016). A common variant in the Setd7 gene predicts serum lycopene concentrations. *Nutrients* 8 (2), 82. Epub 2016/02/11. doi:10.3390/nu8020082

Dinkova-Kostova, A. T., and Talalay, P. (2008). Direct and indirect antioxidant properties of inducers of cytoprotective proteins. *Mol. Nutr. food Res.* 52 (Suppl. 1), S128–S138. Epub 2008/03/11. doi:10.1002/mnfr.200700195

Evans, D. M., and Davey Smith, G. (2015). Mendelian randomization: New applications in the coming age of hypothesis-free causality. *Annu. Rev. genomics Hum. Genet.* 16, 327–350. Epub 2015/05/06. doi:10.1146/annurev-genom-090314-050016

Finck, H., Hart, A. R., Jennings, A., and Welch, A. A. (2014). Is there a role for vitamin C in preventing osteoporosis and fractures? A review of the potential underlying mechanisms and current epidemiological evidence. *Nutr. Res. Rev.* 27 (2), 268–283. Epub 2014/11/22. doi:10.1017/s0954422414000195

Hadji, P., Colli, E., and Regidor, P. A. (2019). Bone health in estrogen-free contraception. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 30 (12), 2391–2400. Epub 2019/08/26. doi:10.1007/s00198-019-05103-6

Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., et al. (2018). The mr-base platform supports systematic causal inference across the human phenome. *eLife* 7, e34408. Epub 2018/05/31. doi:10.7554/eLife.34408

Hendrickson, S. J., Hazra, A., Chen, C., Eliassen, A. H., Kraft, P., Rosner, B. A., et al. (2012). β-Carotene 15,15'-monooxygenase 1 single nucleotide polymorphisms in relation to plasma carotenoid and retinol concentrations in women of European descent. Am. J. Clin. Nutr. 96 (6), 1379–1389. Epub 2012/11/09. doi:10.3945/ajcn. 112.034934

Holvik, K., Ahmed, L. A., Forsmo, S., Gjesdal, C. G., Grimnes, G., Samuelsen, S. O., et al. (2015). No increase in risk of hip fracture at high serum retinol concentrations in community-dwelling older Norwegians: the Norwegian epidemiologic osteoporosis studies. *Am. J. Clin. Nutr.* 102 (5), 1289–1296. Epub 2015/09/18. doi:10.3945/ajcn. 115.110528

Ilesanmi-Oyelere, B. L., Brough, L., Coad, J., Roy, N., and Kruger, M. C. (2019). The relationship between nutrient patterns and bone mineral density in postmenopausal women. *Nutrients* 11 (6), 1262. Epub 2019/06/06. doi:10.3390/nu11061262

Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., et al. (2019). Phenoscanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinforma. Oxf. Engl.* 35 (22), 4851–4853. Epub 2019/06/25. doi:10.1093/ bioinformatics/btz469

Kan, B., Guo, D., Yuan, B., Vuong, A. M., Jiang, D., Zhang, M., et al. (2021). Dietary carotenoid intake and osteoporosis: the national health and nutrition examination survey, 2005-2018. *Archives Osteoporos.* 17 (1), 2. Epub 2021/12/09. doi:10.1007/s11657-021-01047-9

Kanis, J. A. (1997). Diagnosis of osteoporosis. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 7 (Suppl. 3), S108–S116. Epub 1997/01/01. doi:10.1007/bf03194355

Kanis, J. A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. *Lancet London, Engl.* 359 (9321), 1929–1936. Epub 2002/06/12. doi:10.1016/s0140-6736(02) 08761-5

Kanis, J. A., Cooper, C., Rizzoli, R., Reginster, J. Y., and Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis ESCEO and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation IOF (2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 30 (1), 3–44. Epub 2018/10/17. doi:10.1007/ s00198-018-4704-5

Kaur, G., Sharma, A., and Bhatnagar, A. (2021). Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into nrf2-keap1 signalling. *Autoimmunity* 54 (7), 385–397. Epub 2021/08/21. doi:10.1080/08916934.2021.1963959

Kim, M. H., and Lee, H. J. (2016). Osteoporosis, vitamin C intake, and physical activity in Korean adults aged 50 Years and over. J. Phys. Ther. Sci. 28 (3), 725–730. Epub 2016/05/03. doi:10.1589/jpts.28.725

Kim, S. K. (2018). Identification of 613 New loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PloS one* 13 (7), e0200785. Epub 2018/07/27. doi:10.1371/journal.pone.0200785

Kimball, J. S., Johnson, J. P., and Carlson, D. A. (2021). Oxidative stress and osteoporosis. *J. bone Jt. Surg. Am. volume* 103 (15), 1451-1461. Epub 2021/05/21. doi:10.2106/jbjs.20.00989

Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., et al. (2023). Finngen provides genetic insights from a well-phenotyped isolated population. *Nature* 613 (7944), 508–518. Epub 2023/01/19. doi:10.1038/s41586-022-05473-8

Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N., and Davey Smith, G. (2008). Mendelian randomization: using genes as instruments for making causal inferences in Epidemiology. *Statistics Med.* 27 (8), 1133–1163. Epub 2007/09/22. doi:10.1002/sim. 3034

Leder, B. Z., Mitlak, B., Hu, M. Y., Hattersley, G., and Bockman, R. S. (2020). Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis. *J. Clin. Endocrinol. metabolism* 105 (3), 938–943. Epub 2019/11/02. doi:10. 1210/clinem/dgz162

Li, H., Chen, L., Yuan, C., Yang, H., Ma, Z., and Zuo, J. (2023). Diet-derived antioxidants and osteoporosis: a mendelian randomization study. *PloS one* 18 (11), e0293145. Epub 2023/11/29. doi:10.1371/journal.pone.0293145

Liang, Q. L., Xu, H. G., Yu, L., Ding, M. R., Li, Y. T., Qi, G. F., et al. (2023). Bindinginduced fibrillogenesis peptide inhibits rankl-mediated osteoclast activation against osteoporosis. *Biomaterials* 302, 122331. Epub 2023/09/24. doi:10.1016/j.biomaterials. 2023.122331

Liu, J., Curtis, E. M., Cooper, C., and Harvey, N. C. (2019). State of the art in osteoporosis risk assessment and treatment. *J. Endocrinol. investigation* 42 (10), 1149–1164. Epub 2019/04/14. doi:10.1007/s40618-019-01041-6

Long, T., Hicks, M., Yu, H. C., Biggs, W. H., Kirkness, E. F., Menni, C., et al. (2017). Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. *Nat. Genet.* 49 (4), 568–578. Epub 2017/03/07. doi:10.1038/ng.3809

López-Armada, M. J., Fernández-Rodríguez, J. A., and Blanco, F. J. (2022). Mitochondrial dysfunction and oxidative stress in rheumatoid arthritis. *Antioxidants Basel, Switz.* 11 (6), 1151. Epub 2022/06/25. doi:10.3390/antiox11061151

Malmir, H., Shab-Bidar, S., and Djafarian, K. (2018). Vitamin C intake in relation to bone mineral density and risk of hip fracture and osteoporosis: a systematic review and meta-analysis of observational studies. Br. J. Nutr. 119 (8), 847–858. Epub 2018/04/13. doi:10.1017/s0007114518000430

Manolagas, S. C. (2018). The quest for osteoporosis mechanisms and rational therapies: how far we've come, how much further we need to go. *J. bone mineral Res. official J. Am. Soc. Bone Mineral Res.* 33 (3), 371–385. Epub 2018/02/07. doi:10. 1002/jbmr.3400

Medina-Gomez, C., Kemp, J. P., Trajanoska, K., Luan, J., Chesi, A., Ahluwalia, T. S., et al. (2018). Life-course genome-wide association study meta-analysis of total body bmd and assessment of age-specific effects. *Am. J. Hum. Genet.* 102 (1), 88–102. Epub 2018/01/06. doi:10.1016/j.ajhg.2017.12.005

Mladenov, M., Lubomirov, L., Grisk, O., Avtanski, D., Mitrokhin, V., Sazdova, I., et al. (2023). Oxidative stress, reductive stress and antioxidants in vascular pathogenesis and aging. *Antioxidants Basel, Switz.* 12 (5), 1126. Epub 2023/05/27. doi:10.3390/antiox12051126

Mondul, A. M., Yu, K., Wheeler, W., Zhang, H., Weinstein, S. J., Major, J. M., et al. (2011). Genome-wide association study of circulating retinol levels. *Hum. Mol. Genet.* 20 (23), 4724–4731. Epub 2011/09/01. doi:10.1093/hmg/ddr387

New, S. A., Bolton-Smith, C., Grubb, D. A., and Reid, D. M. (1997). Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women. *Am. J. Clin. Nutr.* 65 (6), 1831–1839. Epub 1997/06/01. doi:10.1093/ajcn/65.6.1831

Ni, Y., Zhang, Y., Sun, J., Zhao, L., Wu, B., and Ye, J. (2023). The effect of antioxidant dietary supplements and diet-derived circulating antioxidants on vitiligo outcome: evidence from genetic association and comprehensive mendelian randomization. *Front. Nutr.* 10, 1280162. Epub 2024/01/26. doi:10.3389/fnut.2023.1280162

Palmer, T. M., Lawlor, D. A., Harbord, R. M., Sheehan, N. A., Tobias, J. H., Timpson, N. J., et al. (2012). Using multiple genetic variants as instrumental variables for modifiable risk factors. *Stat. methods Med. Res.* 21 (3), 223–242. Epub 2011/01/11. doi:10.1177/0962280210394459

Platt, I. D., Josse, A. R., Kendall, C. W., Jenkins, D. J., and El-Sohemy, A. (2011). Postprandial effects of almond consumption on human osteoclast precursors--an *ex vivo* study. *Metabolism Clin. Exp.* 60 (7), 923–929. Epub 2010/10/16. doi:10.1016/j. metabol.2010.08.012

Podmore, I. D., Griffiths, H. R., Herbert, K. E., Mistry, N., Mistry, P., and Lunec, J. (1998). Vitamin C exhibits pro-oxidant properties. *Nature* 392 (6676), 559. Epub 1998/04/29. doi:10.1038/33308

Reid, D. M., and New, S. A. (1997). Nutritional influences on bone mass. Proc. Nutr. Soc. 56 (3), 977–987. Epub 1998/03/04. doi:10.1079/pns19970103

Sahni, S., Hannan, M. T., Blumberg, J., Cupples, L. A., Kiel, D. P., and Tucker, K. L. (2009). Protective effect of total carotenoid and lycopene intake on the risk of hip

fracture: a 17-year follow-up from the framingham osteoporosis study. *J. bone mineral Res. official J. Am. Soc. Bone Mineral Res.* 24 (6), 1086–1094. Epub 2009/01/14. doi:10. 1359/jbmr.090102

Shi, W. Q., Liu, J., Cao, Y., Zhu, Y. Y., Guan, K., and Chen, Y. M. (2016). Association of dietary and serum vitamin E with bone mineral density in middle-aged and elderly Chinese adults: a cross-sectional study. *Br. J. Nutr.* 115 (1), 113–120. Epub 2015/10/29. doi:10.1017/s0007114515004134

Shin, S. Y., Fauman, E. B., Petersen, A. K., Krumsiek, J., Santos, R., Huang, J., et al. (2014). An atlas of genetic influences on human blood metabolites. *Nat. Genet.* 46 (6), 543–550. Epub 2014/05/13. doi:10.1038/ng.2982

Simon, J. A., and Hudes, E. S. (2001). Relation of ascorbic acid to bone mineral density and self-reported fractures among us adults. *Am. J. Epidemiol.* 154 (5), 427–433. Epub 2001/09/05. doi:10.1093/aje/154.5.427

Song, S., Guo, Y., Yang, Y., and Fu, D. (2022). Advances in pathogenesis and therapeutic strategies for osteoporosis. *Pharmacol. Ther.* 237, 108168. Epub 2022/03/ 15. doi:10.1016/j.pharmthera.2022.108168

Sugiura, M., Nakamura, M., Ogawa, K., Ikoma, Y., Ando, F., Shimokata, H., et al. (2011). Dietary patterns of antioxidant vitamin and carotenoid intake associated with bone mineral density: findings from post-menopausal Japanese female subjects. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 22 (1), 143–152. Epub 2010/05/19. doi:10.1007/ s00198-010-1239-9

Talaulikar, V. S., Chambers, T., and Manyonda, I. (2012). Exploiting the antioxidant potential of a common vitamin: could vitamin C prevent postmenopausal osteoporosis? *J. obstetrics Gynaecol. Res.* 38 (1), 253–257. Epub 2011/08/11. doi:10.1111/j.1447-0756. 2011.01629.x

Tanaka, M., Inoue, H., Takahashi, N., and Uehara, M. (2023). Ampk negatively regulates rankl-induced osteoclast differentiation by controlling oxidative stress. *Free Radic. Biol. Med.* 205, 107–115. Epub 2023/06/04. doi:10.1016/j.freeradbiomed.2023. 05.033

Tang, Y., Xu, X., Zhang, S., Kong, W., Zhang, W., and Zhu, T. (2023). Genetic liability for diet-derived circulating antioxidants, oxidative stress, and risk of osteoarthritis: a mendelian randomization study. *Front. Nutr.* 10, 1233086. Epub 2024/01/05. doi:10. 3389/fnut.2023.1233086

Tew, M., Catchpool, M., Furler, J., De La Rue, K., Clarke, P., Manski-Nankervis, J. A., et al. (2023). Site-specific factors associated with clinical trial recruitment efficiency in general practice settings: a comparative descriptive analysis. *Trials* 24 (1), 164. Epub 2023/03/04. doi:10.1186/s13063-023-07177-4

Wallace, T. C. (2017). Dried plums, prunes and bone health: a comprehensive review. *Nutrients* 9 (4), 401. Epub 2017/04/20. doi:10.3390/nu9040401

Warensjö Lemming, E., Byberg, L., Melhus, H., Wolk, A., and Michaëlsson, K. (2017). Long-term *a posteriori* dietary patterns and risk of hip fractures in a cohort of women. *Eur. J. Epidemiol.* 32 (7), 605–616. Epub 2017/06/07. doi:10.1007/ s10654-017-0267-6

Wright, N. C., Saag, K. G., Dawson-Hughes, B., Khosla, S., and Siris, E. S. (2017). The impact of the New national bone health alliance (nbha) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 28 (4), 1225–1232. Epub 2016/12/15. doi:10.1007/s00198-016-3865-3

Wu, A. M., Huang, C. Q., Lin, Z. K., Tian, N. F., Ni, W. F., Wang, X. Y., et al. (2014). The relationship between vitamin a and risk of fracture: meta-analysis of prospective

studies. J. bone mineral Res. official J. Am. Soc. Bone Mineral Res. 29 (9), 2032-2039. Epub 2014/04/05. doi:10.1002/jbmr.2237

Wu, Y., Byrne, E. M., Zheng, Z., Kemper, K. E., Yengo, L., Mallett, A. J., et al. (2019). Genome-wide association study of medication-use and associated disease in the UK Biobank. *Nat. Commun.* 10 (1), 1891. Epub 2019/04/25. doi:10.1038/s41467-019-09572-5

Xu, Y., Song, D., Lin, X., Peng, H., Su, Y., Liang, J., et al. (2023). Corylifol a protects against ovariectomized-induced bone loss and attenuates rankl-induced osteoclastogenesis via ros reduction, erk inhibition, and Nfatc1 activation. *Free Radic. Biol. Med.* 196, 121–132. Epub 2023/01/18. doi:10.1016/j.freeradbiomed.2023. 01.017

Yang, T. C., Duthie, G. G., Aucott, L. S., and Macdonald, H. M. (2016). Vitamin E homologues α- and γ-tocopherol are not associated with bone turnover markers or bone mineral density in peri-menopausal and post-menopausal women. *Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A.* 27 (7), 2281–2290. Epub 2016/05/04. doi:10.1007/ s00198-015-3470-x

Yuan, Y., Yang, J., Zhuge, A., Li, L., and Ni, S. (2022). Gut microbiota modulates osteoclast glutathione synthesis and mitochondrial biogenesis in mice subjected to ovariectomy. *Cell Prolif.* 55 (3), e13194. Epub 2022/01/27. doi:10.1111/cpr. 13194

Zhang, J., Hu, X., and Zhang, J. (2017b). Associations between serum vitamin E concentration and bone mineral density in the us elderly population. Osteoporos. Int. a J. established as result Coop. between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A. 28 (4), 1245–1253. Epub 2016/12/03. doi:10.1007/s00198-016-3855-5

Zhang, X., Zhang, R., Moore, J. B., Wang, Y., Yan, H., Wu, Y., et al. (2017a). The effect of vitamin a on fracture risk: a meta-analysis of cohort studies. *Int. J. Environ. Res. public health* 14 (9), 1043. Epub 2017/09/12. doi:10.3390/ijerph14091043

Zhang, X., Zhao, H., Man, J., Yin, X., Zhang, T., Yang, X., et al. (2022). Investigating causal associations of diet-derived circulating antioxidants with the risk of digestive system cancers: a mendelian randomization study. *Nutrients* 14 (15), 3237. Epub 2022/08/13. doi:10.3390/nu14153237

Zhao, H., Han, X., Zhang, X., Li, L., Li, Y., Wang, W., et al. (2023). Dissecting causal associations of diet-derived circulating antioxidants with six major mental disorders: a mendelian randomization study. *Antioxidants Basel, Switz.* 12 (1), 162. Epub 2023/01/ 22. doi:10.3390/antiox12010162

Zheng, H. F., Forgetta, V., Hsu, Y. H., Estrada, K., Rosello-Diez, A., Leo, P. J., et al. (2015). Whole-genome sequencing identifies En1 as a determinant of bone density and fracture. *Nature* 526 (7571), 112–117. Epub 2015/09/15. doi:10.1038/nature14878

Zheng, J. S., Luan, J., Sofianopoulou, E., Imamura, F., Stewart, I. D., Day, F. R., et al. (2021). Plasma vitamin C and type 2 diabetes: genome-wide association study and mendelian randomization analysis in European populations. *Diabetes care* 44 (1), 98–106. Epub 2020/11/19. doi:10.2337/dc20-1328

Zhu, J., Lian, J., Wang, X., Wang, R., Pang, X., Xu, B., et al. (2023). Role of endogenous and exogenous antioxidants in risk of six cancers: evidence from the mendelian randomization study. *Front. Pharmacol.* 14, 1185850. Epub 2023/07/13. doi:10.3389/fphar.2023.1185850

Zou, M., Liang, Q., Zhang, W., Liang, J., Zhu, Y., and Xu, Y. (2024). Diet-derived circulating antioxidants and risk of inflammatory bowel disease: a mendelian randomization study and meta-analysis. *Front. Immunol.* 15, 1334395. Epub 2024/03/07. doi:10.3389/fimmu.2024.1334395